⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCYX News
SCYNEXIS, Inc.
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
globenewswire.com
SCYX
Form 8-K
sec.gov
SCYX
Form 8-K
sec.gov
SCYX
Form 8-K
sec.gov
SCYX
SCYNEXIS Announces One-for-Eight Reverse Stock Split
globenewswire.com
SCYX
Poxel publie son chiffre d’affaires pour le premier trimestre 2026 et fait le point sur sa situation
businesswire.com
SCYX
Poxel Reports First Quarter 2026 Revenue and Provides a Business Update
businesswire.com
SCYX
Form 8-K
sec.gov
SXTPW
SXTP
CERO
SCYX
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
SCYX
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
SCYX